

ASX Release**Clarification announcement: Aeroflow agreement****Announcement dated 24 February 2020 — Oventus-Aeroflow agreement to drive further uptake of O₂Vent technology**

26 February 2020: Oventus Medical Ltd (ASX:OVN) (**Oventus**) refers to its announcement made on 24 February 2020 (**Announcement**).

In accordance with ASX Guidance Note 8, Oventus wishes to clarify that the agreement signed with Aeroflow Healthcare Inc. and referenced in the Announcement, has a term of 3 years, with an automatic 3 year renewal, unless a party elects not to renew no later than 180 days prior to the end of the 3 year period.

Oventus also wishes to note further terms to the Aeroflow agreement which are in keeping with other agreements announced under the Oventus 'Lab in lab' program, summarised as follows:

- Aeroflow is a premier provider of DME selling CPAP and associated products and services in the US. The Company is on an aggressive growth path, targeting nationwide expansion and has identified OSA therapeutics as a key growth driver for its business
- Aeroflow has identified seven of its own sites in North Carolina, South Carolina, Tennessee, Alabama, Colorado, Virginia and Michigan for an initial launch
- After these initial launches, Aeroflow intends to launch across the US nationally, as it execute upon an aggressive growth plan
- In addition, Aeroflow has signed a master agreement with Oventus which will see it offer Oventus technology under subcontracts with regional sleep groups nationwide
- Aeroflow has a large existing patient population across the US with sophisticated marketing systems for promotion of Oventus' technology
- In line with other agreements there are minimum quotas of 20 patients to be treated with Oventus' O₂Vent Optima per site, per month once fully operational.

Oventus CEO, Dr Chris Hart commented, "We felt it was important to clarify the significance of this agreement. Aeroflow is a substantial and fast-growing regional sleep group with the ability to partner with us to roll out the lab in lab program and Oventus technology across the US."

—ENDS—

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +1 949 599 8948 or investors@oventus.com.au

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients' access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances, Oventus O2Vent devices manage the entire upper airway via a unique and patented built-in airway. O2Vent devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The O2Vent allows nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airway integrated in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O2Vent Optima device, to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure)

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea¹.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnea treatment³. The O2Vent Optima and ExVent provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

About Aeroflow Healthcare

Aeroflow Healthcare was founded in Asheville, North Carolina in 2001 as a home oxygen provider, and has since grown to become one of the leading DME providers nationwide. For three consecutive years, Aeroflow has been ranked on Inc. Magazine's List of 5000 Fastest Growing Companies. In 2017, Aeroflow was also awarded the HME Excellence Award for Best Home Medical Equipment Provider and has been recognised as a

¹ Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

² Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

³ Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.

O2Vent®



business offering top-notch benefits to employees with the Great Place to Work Award. Aeroflow is an accredited Medicare and Medicaid provider and accepts most commercial insurance. To learn more about Aeroflow Healthcare and getting medical equipment through insurance, visit: aeroflowinc.com.